MSD Animal Health (Merck Animal Health in the U.S.) has introduced FinadyneTransdermal (flunixin meglumine) pour-on solution to reduce fever associated with bovine respiratory disease.

The product is currently only available in European markets.

Finadyne combines convenience with a novel delivery method that simplifies administration for veterinarians and farmers alike, MSD said.

Transdermal non-steroidal anti-inflammatory product demonstrated to reduce fever associated with bovine respiratory disease

"The launch of FinadyneTransdermal Pour-on allows for a more convenient way to relieve animals from fever, improve respiratory and depression scores associated with BRD," said Siddartha Torres, MSD Animal Health. "FinadyneTransdermal Pour-on is the world's first non-parasiticide cattle product available with a transdermal route of administration."

Finadyne Transdermal Pour-on goes to work quickly and has been demonstrated to reduce fever as early as four hours after administration.

The efficient administration means there is no need for additional labor, head gates or restraint that is commonly associated with injectable administration, which translates to reduced cost per treatment, MSD said.

Available in pre-calibrated packaging, Finadyne Transdermal Pour-on makes it easy to ensure the correct dose is given every time. The unique bottle is designed for proper application along the animal's back and the red-colored solution makes it simple to accurately and quickly measure the dose volume for each animal.

"Finadyne Transdermal Pour-on will become an important part of health programs where the reduction of fever associated with BRD is indicated as it makes quick work of treating animals, and supports improved animal well-being," said Martyn Phillips, MSD Animal Health.

This new approach to reducing fever in cattle is in alignment with industry efforts to continuously improve animal care. Transdermal application requires less handling, resulting in less stress on animals and leading to inherent health and wellness advantages. It also offers the added benefit of needle-free administration, with no injection site lesions and a higher-value end product.

Source: MSD Animal Health